UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 237

Sortiert nach

Highly prevalent colorectal cancer-infiltrating LAP⁺ Foxp3⁻ T cells exhibit more potent immunosuppressive activity than Foxp3⁺ regulatory T cells

Mucosal immunology, 2014-03, Vol.7 (2), p.428-439

2014

Link zum Volltext

Verfügbarkeit prüfen

Elevated IL-33 expression is associated with pediatric eosinophilic esophagitis, and exogenous IL-33 promotes eosinophilic esophagitis development in mice

American journal of physiology: Gastrointestinal and liver physiology, 2016-01, Vol.310 (1), p.G13-G25

2016

Link zum Volltext

Verfügbarkeit prüfen

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

European journal of cancer (1990), 2004-03, Vol.40 (5), p.689-695

2004

Link zum Volltext

Verfügbarkeit prüfen

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

British journal of cancer, 2012-08, Vol.107 (4), p.639-645

2012

Link zum Volltext

Verfügbarkeit prüfen

278. Immunological outcome in patients after resection of colorectal cancer

European journal of surgical oncology, 2014-11, Vol.40 (11), p.S111-S111

2014

Link zum Volltext

Verfügbarkeit prüfen

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

British journal of cancer, 2005-10, Vol.93 (8), p.876-883

2005

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours

European journal of cancer (1990), 2004-06, Vol.40 (9), p.1327-1331

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase I II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours

British journal of cancer, 2004-11, Vol.91 (9), p.1651-1655

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours

British journal of cancer, 2004-10, Vol.91 (8), p.1459-1465

2004

Link zum Volltext

Verfügbarkeit prüfen

PMO-088A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression

Gut, 2012-07, Vol.61 (Suppl 2), p.A109-A109

2012

Link zum Volltext

Verfügbarkeit prüfen

PMO-088 A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression

Gut, 2012-07, Vol.61 (Suppl 2), p.A109-A109

2012

Link zum Volltext

Verfügbarkeit prüfen

How to Treat the Ewing's Family of Sarcomas in Adult Patients

The oncologist (Dayton, Ohio), 2006-01, Vol.11 (1), p.65-72

2006

Link zum Volltext

Verfügbarkeit prüfen

PWE-151 Cell-Mediated Immune Recognition of Cea Is Associated with Early Tumour Recurrence Following Resection of Colorectal Cancer

Gut, 2013-06, Vol.62 (Suppl 1), p.A192-A193

2013

Link zum Volltext

Verfügbarkeit prüfen

PWE-151Cell-MediatedImmune Recognition of Cea Is Associated with Early Tumour Recurrence Following Resection of Colorectal Cancer

Gut, 2013-06, Vol.62 (Suppl 1), p.A192-A193

2013

Link zum Volltext

Verfügbarkeit prüfen

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

Cancer chemotherapy and pharmacology, 2005-04, Vol.55 (4), p.379-386

2005

Link zum Volltext

Verfügbarkeit prüfen

9421 The role of chemotherapy in aggressive fibromatosis

European journal of cancer supplements, 2009, Vol.7 (2), p.596-596

2009

Link zum Volltext

Verfügbarkeit prüfen

9404 A Phase II study of cediranib in patients with metastatic gastrointestinal stromal tumours (GIST) and metastatic soft tissue sarcoma (STS) (including alveolar soft part sarcoma [ASPS])

European journal of cancer supplements, 2009, Vol.7 (2), p.591-591

2009

Link zum Volltext

Verfügbarkeit prüfen

PWE-152 Selective Loss of Oncofoetal Antigen 5T4-Specific T Cell Response Correlates with Progression of Colorectal Cancer

Gut, 2013-06, Vol.62 (Suppl 1), p.A193-A193

2013

Link zum Volltext

Verfügbarkeit prüfen

PWE-152SelectiveLoss of Oncofoetal Antigen 5T4-Specific T Cell Response Correlates with Progression of Colorectal Cancer

Gut, 2013-06, Vol.62 (Suppl 1), p.A193-A193

2013

Link zum Volltext

Verfügbarkeit prüfen

49 POSTER Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI)

European journal of cancer supplements, 2008, Vol.6 (12), p.19-19

2008

Link zum Volltext

Verfügbarkeit prüfen

126 INVITED New drug treatment for cancer in 2007 – real progress at last?

European journal of cancer supplements, 2007, Vol.5 (4), p.35-35

2007

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant and Adjuvant Therapy for Extremity Soft Tissue Sarcomas

Hematology/oncology clinics of North America, 2005-06, Vol.19 (3), p.489-500

2005

Link zum Volltext

Verfügbarkeit prüfen

388 POSTER Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma

European journal of cancer supplements, 2008, Vol.6 (12), p.122-122

2008

Link zum Volltext

Verfügbarkeit prüfen

7505 ORAL Personalized therapy with trabectedin (Yondelis®) in advanced pre-treated sarcomas

European journal of cancer supplements, 2007, Vol.5 (4), p.403-404

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 237

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(221)
Mit Volltextzugriff
(213)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(135)
Life Sciences & Biomedicine
(107)
Humans
(106)
Female
(52)
Male
(43)
Adult
(37)
Middle Aged
(32)
Biological And Medical Sciences
(29)
Medical Sciences
(29)
Aged
(27)
Oncology
(24)
Physical Sciences
(23)
Technology
(21)
Animals
(19)
Chemistry
(18)
Surgery
(18)
Radiology, Nuclear Medicine & Medical Imaging
(17)
Materials Science
(16)
Tumors
(16)
Genetics & Heredity
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Highly prevalent colorectal cancer-infiltrating LAP⁺ Foxp3⁻ T cells exhibit more potent immunosuppressive activity than Foxp3⁺ regulatory T cells

Elevated IL-33 expression is associated with pediatric eosinophilic esophagitis, and exogenous IL-33 promotes eosinophilic esophagitis development in mice

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

278. Immunological outcome in patients after resection of colorectal cancer

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours

Phase I II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours

PMO-088A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression

PMO-088 A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression

How to Treat the Ewing's Family of Sarcomas in Adult Patients

PWE-151 Cell-Mediated Immune Recognition of Cea Is Associated with Early Tumour Recurrence Following Resection of Colorectal Cancer

PWE-151Cell-MediatedImmune Recognition of Cea Is Associated with Early Tumour Recurrence Following Resection of Colorectal Cancer

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

9421 The role of chemotherapy in aggressive fibromatosis

9404 A Phase II study of cediranib in patients with metastatic gastrointestinal stromal tumours (GIST) and metastatic soft tissue sarcoma (STS) (including alveolar soft part sarcoma [ASPS])

PWE-152 Selective Loss of Oncofoetal Antigen 5T4-Specific T Cell Response Correlates with Progression of Colorectal Cancer

PWE-152SelectiveLoss of Oncofoetal Antigen 5T4-Specific T Cell Response Correlates with Progression of Colorectal Cancer

49 POSTER Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI)

126 INVITED New drug treatment for cancer in 2007 – real progress at last?

Neoadjuvant and Adjuvant Therapy for Extremity Soft Tissue Sarcomas

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

388 POSTER Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma

7505 ORAL Personalized therapy with trabectedin (Yondelis®) in advanced pre-treated sarcomas

Suchergebnisse filtern